Haleon Paying $221M For Full Control Of Chinese Pharma JV
British consumer healthcare company Haleon PLC said Tuesday it has agreed to purchase the remaining 12% stake in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co., for 1.623 billion yuan ($221...To view the full article, register now.
Already a subscriber? Click here to view full article